A cancer-targeting antibody that helps the body's immune cells spot and destroy hard-to-treat tumors such as triple-negative ...

Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or ...

Antibodies that specifically bind a protein upregulated in leukemia effectively treat cancer. Researchers now present new insights into how antibody types impact the potency and safety of such ...

A new study published in the journal Nature Medicine in February 2020 reports that the administration of neutralizing antibodies against HIV improve the recipient’s specific T cell responses against ...

Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer. Researchers ...

Type 1 diabetes mellitus is a T-cell–mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be ...

Teplizumab has shown significant preservation of C-peptide levels in newly diagnosed type 1 diabetes (T1D) patients, indicating the potential for modifying disease progression. Combining teplizumab ...

Scientists compared the blood of nearly 300 individuals with type 1 diabetes to healthy controls, they found that a higher level of antibodies against gentamicin was associated with increased risk of ...

In the aftermath of those cases, some practitioners have suggested means-plus-function claiming as one strategy to obtain antibody claims that are broader in scope than the specific antibodies ...

Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is ...